Cancellation of state registration. Abilifay®

December 9, 2016
Active substances:
Trade names:
ICD-10:
V.F20-F29.F20    Schizophrenia
V.F20-F29.F21    Chrysotile disorder
V.F20-F29.F22    Chronic delusional disorders
V.F20-F29.F23    Acute and transient psychotic disorders
V.F20-F29.F25    Schizoaffective disorder
V.F20-F29.F29    Inorganic psychosis, unspecified
V.F30-F39.F30    Manic episode
V.F30-F39.F31    Bipolar affective disorder
Abilifay, aripiprazole, schizophrenia, schizophrenia, schizotypic disorder, psychosis, affective disorder, schizoaffective disorder

The Ministry of Health of the Russian Federation in accordance with Article 32 of the Federal Law of 12.04.2010 No. 61-FZ "On the circulation of medicines" decided to abolish state registration and exclude from the state register of medicines for medical use of the medicinal product (registration certificate LS-001812 from 06.08.2010 issued by Bristol-Myers Squibb Company, USA):

Abilifay® (trade name of the medicinal product)

Aripiprazole (international non-proprietary or grouping or chemical name)

tablets, 5 mg, 10 mg, 15 mg, 30 mg (dosage form, dosage)

Bristol-Myers Squibb Sr.L., Italy Localita Fontana del Ceraso, 03012 Anagni (FR), Italy (name and address of the location of the manufacturer of the medicinal product)

on the basis of filing an application by the authorized legal entity LLC Bristol-Myers Squibb to cancel the state registration of the medicinal product.